Cedars Sinai

Aggressive papillary thyroid carcinoma variants appeared associated with a wide range of survival outcomes, suggesting greater emphasis should be placed on tailored treatment approaches for patients with histologically and prognostically distinct subtypes, according to study results published in JAMA Oncology.

Patient-reported adverse effect profiles 5 years after contemporary treatment for localized prostate cancer could help inform treatment choices for this patient population, according to study results published in JAMA.

An FDA advisory committee today voted 2-13 against recommending approval of padeliporfin di-potassium, a minimally invasive treatment for localized prostate cancer.

More than a century has passed since neurosurgeon and pathologist Harvey Cushing described the disease that would eventually bear his name, but only recently have several key discoveries offered patients with the condition real hope for a cure.

KOLOA, Hawaii — Patients with thyroid eye disease treated with teprotumumab demonstrated a significant reduction in proptosis compared with those treated with placebo, according to phase 3 results from the OPTIC trial.

In my clinic, it still feels like we get countless referrals for irritable bowel syndrome.

A research team led by physician-scientists from Cedars-Sinai was awarded $10 million from the Department of Defense to study risk factors and behaviors that contribute to pancreatic diseases, according to a press release.

There are endless idioms about blood. It is thicker than water, but one cannot get it from a stone. Truman Capote wrote about the cold version, rock band Foreigner sang about the hot version. When it comes to rheumatic diseases, researchers are out for blood — blood-based biomarkers, that is.

Patients with cancer had an increased risk for takotsubo syndrome, also known as broken heart syndrome, according to a study published in the Journal of the American Heart Association.

Nivolumab demonstrated limited activity among patients with untreated brain metastases from clear cell renal cell carcinoma who experienced progression after vascular endothelial growth factor receptor-directed therapy, according to results of a phase 2 study published in Journal of Clinical Oncology.